Last update Aug. 28, 2020

C33 H30 N4 O2

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is an angiotensin II receptor antagonist with actions similar to those of losartan.
It is indicated in the treatment of hypertension.
Oral administration once a day.

At latest update, relevant published data on excretion into breast milk were not found.

Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely.

However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability (Tamargo 2006). The latter properties make it less convenient for use while breastfeeding.

Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy (Pietrement 2003).

Until more data on this medication is available safer alternative drugs are preferred (Malachias 2016, Rowe 2013) especially in premature babies or during the neonatal period.

Alternatives

  • Candesartan Cilexetil ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Enalapril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Quinapril Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C33 H30 N4 O2 is Telmisartan in Molecular formula.

Is written in other languages:

Group

C33 H30 N4 O2 belongs to this group or family:

Tradenames

Main tradenames from several countries containing C33 H30 N4 O2 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 40 - 58 %
Molecular weight 515 daltons
Protein Binding 100 %
VD 6.9 l/Kg
Tmax 1 - 3 hours
24 hours

References

  1. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. Boe.Ing. Telmisartan. Drug Summary. 2013 Full text (in our servers)
  4. AEMPS. Telmisartán. Ficha técnica. 2010 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)
  6. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol. 2003 Abstract Full text (link to original source) Full text (in our servers)

Total visits

921

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM